There has never been more excitement around wellness, medical weight loss, and GLP-1 weight loss shots like semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro). These medications have transformed how we approach obesity, a chronic, metabolic disease driven by biology, not willpower.
But with the surge in popularity comes one question almost every patient asks:
“Do I have to be on this forever?”
As an obesity medicine specialist and bariatric surgeon, I answer this every day.
The honest answer is: YES. For most people, long-term therapy is required.
But there’s an important caveat: your biology determines your response.
New evidence, especially from Eli Lilly’s SURMOUNT-4 trial, helps us clarify who succeeds long-term, who rebounds, and how GLP-1 medications compare to bariatric surgery, still the most effective weight-loss tool available.
Let’s break down what the science actually shows.
The SURMOUNT-4 trial is one of the most important long-term studies ever published on Tirzepatide (Zepbound/Mounjaro). Its findings should guide every patient considering medical weight loss.
After 36 weeks of tirzepatide treatment, participants were randomized either to continue the medication or stop it (placebo).
Here’s what the study showed:
✔️ Patients Who Stopped Tirzepatide Regained Most of the Weight
“82% of participants who discontinued tirzepatide regained at least 25% of their initial weight loss within one year.”
This parallels what earlier semaglutide research found showing significant regain occurs shortly after stopping treatment.
✔️ Patients Who Stayed on Tirzepatide Maintained or Continued Losing Weight
Those who continued Tirzepatide maintained their weight loss, with many losing additional weight beyond the initial phase.
✔️ Stopping the Medication Reversed Cardiometabolic Benefits
“Cardiometabolic improvements (blood pressure, glucose, cholesterol, waist circumference) reverted toward baseline in participants who switched to placebo.”
This confirms a critical truth:
👉 Obesity is a chronic disease requiring chronic treatment.
👉 Stopping the medication is like stopping treatment for any chronic disease like diabetes or hypertension.
Not everyone responds the same way to semaglutide or tirzepatide. In fact, the long-term data clearly show patterns:
Super Responders Tend to Be:
✔️ People with less weight to lose
✔️ Those who lose weight quickly
✔️ Those who lose a higher percentage of total body weight
✔️ Smaller-bodied individuals (naturally lean or lower BMI)
✔️ Patients who have had bariatric surgery, especially gastric bypass
After bariatric surgery, your gastrointestinal hormones, including GLP-1, are already elevated.
Taking a GLP-1 medication amplifies this effect, often making the patient:
✨ Lose more weight
✨ Lose it quicker
✨ Keep weight off more effectively
✨ Break long-standing plateaus
This is why someone who was a “non-responder” before surgery can become a super responder after surgery.
The data show that patients who:
are significantly more likely to regain most or all of the weight when they stop the medication.
This is not your fault.
This is biology: genetic variability, metabolic adaptations, hormonal signaling, and energy-homeostasis pathways.
Because response varies widely, support must be personalized.
A concierge-style medical weight loss program can:
The more sensitive you are to medication, the more important individualized care becomes.
For patients with BMI > 30 kg/m², I strongly recommend considering bariatric surgery first.
Here’s why:
⭐ 1. Bariatric surgery offers unmatched long-term effectiveness
Decades of data show sustained weight loss and improved metabolic health.
⭐ 2. It’s more cost-effective over time
GLP-1 therapy often requires lifelong treatment with significant cost. Surgery is a one-time investment with long-lasting benefits.
⭐ 3. Surgery + GLP-1 = the best modern combination
If you hit a plateau, struggle with regain, or want additional improvement, medications like semaglutide or tirzepatide enhance surgical results.
⭐ 4. Bariatric surgery creates physiological changes GLP-1s cannot fully replace
Changes in gut hormones, bile acids, microbiome, and vagal signaling work synergistically to lower your biological set point.
There’s no one-size-fits-all answer but there is a right answer for you.
This combined approach represents the most modern, evidence-based way to treat obesity.
Based on extensive evidence, the conclusion is clear:
✔️ Most patients will need long-term therapy
✔️ Stopping leads to predictable regain
✔️ Bariatric surgery remains the most durable solution
✔️ Combination therapy offers the best of both worlds
✔️ Obesity is a chronic disease.
And the most important factor?
A personalized plan tailored to your biology, genetics, metabolism, lifestyle, and goals.
We would love to help you understand your options with a VIRTUAL consultation.
We’ll discuss your struggles, goals, metabolic profile, surgical candidacy, and the safest and most effective way forward for you.
👉 Text us at 407-543-0971
👉 Or request a VIRTUAL consult at at BodyByBariatrics.com
Your journey deserves expert guidance and a plan that works for the rest of your life.
Listen to our recent The Weight Loss Collab Podcast where I dish on all the details of these medications!
If you’re ready to explore your options, schedule a virtual consultation with our team. We’ll evaluate your history, review your BMI, goals, comorbidities, and build a roadmap that fits you. Whether you are considering medication only, surgery only, or combined approach, we’ll guide you.
🦋
XOXO,
Dr. Betsy Dovec
Disclaimer: This blog does not replace medical advice. Please consult a healthcare provider for personalized guidance.
